报价延迟最少15分钟:2026/04/04 00:53 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.54 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.15/1.33
|
|
企业价值
1.03B
|
| 资产负债 |
|
每股账面净值
-1.61
|
| 现金流量 |
|
现金流量率
0.20
|
| 损益表 |
|
收益
296.15M
|
|
每股收益
2.63
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries. |
